At a glance
- Originator Servier
- Class Antineoplastics
- Mechanism of Action Angiogenesis inhibitors; Chelating agents; Gelatinase inhibitors; Metalloprotease inhibitors; Peptide hydrolase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 06 Nov 2003 No development reported - Preclinical for Cancer in France (unspecified route)
- 02 Feb 1999 Preclinical development for Cancer in France (Unknown route)